Subcutaneous Immune Globulin (SCIG 20%) and Facilitated Subcutaneous Immunoglobulin (fSCIG) Treatment in Polish Paediatric Patients With Primary Immunodeficiencies (PID) - Retrospective Medical Chart Review Study
Latest Information Update: 18 Nov 2021
At a glance
- Drugs Immune globulin (Primary)
- Indications Immunodeficiency disorders
- Focus Therapeutic Use
- Acronyms IG-TATRY
- Sponsors Shire
- 15 Nov 2021 Status changed from recruiting to completed.
- 27 Aug 2021 Planned End Date changed from 1 Jul 2021 to 30 Sep 2021.
- 27 Aug 2021 Planned primary completion date changed from 1 Jul 2021 to 30 Sep 2021.